- Home
- WDH vs ZVRA Comparison
WDH vs ZVRA Comparison
Compare WDH & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDH
- ZVRA
- Stock Information
- Founded
- WDH 2016
- ZVRA 2006
- Country
- WDH China
- ZVRA United States
- Employees
- WDH N/A
- ZVRA N/A
- Industry
- WDH Specialty Insurers
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- WDH Finance
- ZVRA Health Care
- Exchange
- WDH Nasdaq
- ZVRA Nasdaq
- Market Cap
- WDH 420.6M
- ZVRA 473.6M
- IPO Year
- WDH 2021
- ZVRA 2015
- Fundamental
- Price
- WDH $1.11
- ZVRA $9.09
- Analyst Decision
- WDH
- ZVRA Strong Buy
- Analyst Count
- WDH 0
- ZVRA 7
- Target Price
- WDH N/A
- ZVRA $21.20
- AVG Volume (30 Days)
- WDH 143.3K
- ZVRA 677.5K
- Earning Date
- WDH 12-05-2024
- ZVRA 11-12-2024
- Dividend Yield
- WDH 4.29%
- ZVRA N/A
- EPS Growth
- WDH N/A
- ZVRA N/A
- EPS
- WDH 0.10
- ZVRA N/A
- Revenue
- WDH $375,221,621.00
- ZVRA $24,489,000.00
- Revenue This Year
- WDH N/A
- ZVRA N/A
- Revenue Next Year
- WDH $8.44
- ZVRA $318.48
- P/E Ratio
- WDH $11.96
- ZVRA N/A
- Revenue Growth
- WDH N/A
- ZVRA 47.85
- 52 Week Low
- WDH $0.94
- ZVRA $4.20
- 52 Week High
- WDH $1.53
- ZVRA $9.30
- Technical
- Relative Strength Index (RSI)
- WDH 43.86
- ZVRA 59.84
- Support Level
- WDH $1.10
- ZVRA $8.32
- Resistance Level
- WDH $1.15
- ZVRA $9.27
- Average True Range (ATR)
- WDH 0.06
- ZVRA 0.53
- MACD
- WDH -0.00
- ZVRA 0.00
- Stochastic Oscillator
- WDH 40.00
- ZVRA 81.82
About WDH Waterdrop Inc. (each representing the right to receive 10)
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. It is a third-party insurance platform in China in terms of life and health insurance.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.